Proactive Investors - Run By Investors For Investors

Race Oncology to reveal regulatory developments

Race Oncology's shares are currently in pre-open pending the update.
Race Oncology to reveal regulatory developments
The company has a focus on chemotherapy drugs

Race Oncology Ltd (ASX:RAC) has been granted a trading halt by the ASX this morning, pending details in relation to regulatory developments in the UK.

Race’s business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma.

The company’s first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies.

The halt will remain in place until the opening of trade on Friday 22 June 2018, or earlier if an announcement is made to the market.

View full RAC profile View Profile

Race Oncology Ltd Timeline

February 15 2017

Related Articles

scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use